A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients

Pulmonary Pharmacology and Therapeutics

Volumn 40, Issue , 2016, Pages 1-6

  Singh, D ^a   Leaker, B ^b   Boyce, M ^c   Nandeuil, M A ^d   Collarini, S ^e   Mariotti, F ^e   Santoro, D ^e   Barnes, P J ^f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b RESPIRATORY CLINICAL TRIALS LTD   (United Kingdom)

^c Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

^d Laboratoire Chiesi   (France)

^e CHIESI FARMACEUTICI S P A   (Italy)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Allergen challenge; CHF6001; PDE4 inhibitor

Indexed keywords

CHF 6001; METHACHOLINE; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG; 3,5-DICHLORO-4-(2-(3-(CYCLOPROPYLMETHOXY)-4-(DIFLUOROMETHOXY)PHENYL)-2-(3-(CYCLOPROPYLMETHOXY)-4-(METHYLSULFONAMIDO)BENZOYLOXY)ETHYL)PYRIDINE 1-OXIDE; 4 AMINOBENZOIC ACID DERIVATIVE; ALLERGEN; SULFONAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CAT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMATOPHAGOIDES; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER INHALER; DYSPEPSIA; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; GRASS POLLEN; HEADACHE; HUMAN; LATE ASTHMATIC RESPONSE; LEUKOCYTE DIFFERENTIAL COUNT; LUNG FUNCTION TEST; MALE; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; DOSE RESPONSE; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SPUTUM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; ALLERGENS; ASTHMA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRY POWDER INHALERS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PARA-AMINOBENZOATES; PHOSPHODIESTERASE 4 INHIBITORS; SPUTUM; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84978280542     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2016.06.011     Document Type: Article

References (24)

1. [1] Tasken, K., Aandahl, E.M., Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 84 (2004), 137–167.
2. [2] Page, C.P., Spina, D., Selective PDE inhibitors as novel treatments for respiratory diseases. Curr. Opin. Pharmacol. 12:3 (2012 Jun), 275–286.
3. [3] Martinez, F.J., Calverley, P.M., Goehring, U.M., Brose, M., Fabbri, L.M., Rabe, K.F., Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385:9971 (2015 Mar 7), 857–866.
4. [4] Wedzicha, J.A., Rabe, K.F., Martinez, F.J., Bredenbröker, D., Brose, M., Goehring UM,Calverley, P.M., Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 143:5 (2013), 1302–1311.
5. [5] Chervinsky, P., Meltzer, E.O., Busse, W., Ohta, K., Bardin, P., Bredenbröker, D., Bateman, E.D., Roflumilast for asthma: safety findings from a pooled analysis of ten clinical studies. Pulm. Pharmacol. Ther., 35(Suppl. S28–34), 2015.
6. [6] Meltzer, E.O., Chervinsky, P., Busse, W., Ohta, K., Bardin, P., Bredenbröker, D., Bateman, E.D., Roflumilast for asthma: efficacy findings in placebo-controlled studies. Pulm. Pharmacol. Ther., 35(Suppl. S20–7), 2015 Dec.
7. [7] Moretto, N., Caruso, P., Bosco, R., Marchini, G., Pastore, F., Armani, E., et al. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. J. Pharmacol. Exp. Ther. 352 (2015), 559–567.
8. [8] Singh, S.D., Richards, D., Knowles, R.G., Schwartz, S., Woodcock, A.A., Langley, S.J., O'Connor, B.J., Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am. J. Respir. Crit. Care Med. 176 (2007), 988–993.
9. [9] Singh, D., Cadden, P., Hunter, M., Pearce Collins, L., Perkins, M., Pettipher, R., Townsend, E., Vinall, S., O'Connor, B., Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur. Respir. J. 41 (2013), 46–52.
10. [10] Wenzel, S., Wilbraham, D., Fuller, R., Getz, E.B., Longphre, M., Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370 (2007), 1422–1431.
11. [11] Gauvreau, G.M., Boulet, L.P., Schmid-Wirlitsch, C., Côté, J., Duong, M., Killian, K.J., et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir. Res., 12, 2011, 140.
12. [12] Pizzichini, E., Pizzichini, M.M., Efthimiadis, A., Evans, S., Morris, M.M., Squillace, D., Gleich, G.J., Dolovich, J., Hargreave, F.E., Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am. J. Respir. Crit. Care Med. 154:2 Pt 1 (1996 Aug), 308–317.
13. [13] Bardin, P., Kanniess, F., Gauvreau, G., Bredenbröker, D., Rabe, K.F., Roflumilast for asthma: efficacy findings in mechanism of action studies. Pulm. Pharmacol. Ther., 35(Suppl:S4-S10), 2015.
14. [14] O'Byrne, P.M., Allergen-induced airway inflammation and its therapeutic intervention. Allergy Asthma Immunol. Res. 1 (2009), 3–9.
15. [15] van Schalkwyk, E., Strydom, K., Williams, Z., Venter, L., Leichtl, S., Schmid-Wirlitsch, C., et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol. 116 (2005), 292–298.
16. [16] Leaker, B.R., Singh, D., Ali, F.Y., Barnes, P.J., O'Connor, B., The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm. Med., 14, 2014, 166.
17. [17] Singh, D., Petavy, F., Macdonald, A.J., Lazaar, A.L., O'Connor, B.J., The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir. Res., 11, 2010, 26.
18. [18] Palmqvist, M., Bruce, C., Sjöstrand, M., Arvidsson, P., Lötvall, J., Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy 60 (2005), 65–70.
19. [19] Duong, M., Gauvreau, G., Watson, R., Obminski, G., Strinich, T., Evans, M., et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J. Allergy Clin. Immunol. 119 (2007), 322–327.
20. [20] Harbinson, P.L., MacLeod, D., Hawksworth, R., O'Toole, S., Sullivan, P.J., Heath, P., et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur. Respir. J. 10 (1997), 1008–1014.
21. [21] Lipari, M., Kale-Pradhan, P.B., Vulnerable COPD patients with comorbidities: the role of roflumilast. Ther. Clin. Risk Manag. 10 (2014), 969–976.
22. [22] Imaoka, H., Gauvreau, G.M., Watson, R.M., Strinich, T., Obminksi, G.L., Howie, K., Killian, K.J., O'Byrne, P.M., Sputum inflammatory cells and allergen-induced airway responses in allergic asthmatic subjects. Allergy 66 (2011), 1075–1080.
23. [23] Kent, S.E., Boyce, M., Diamant, Z., Singh, D., O'Connor, B.J., Saggu, P.S., Norris, V., The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin. Exp. Allergy 43 (2013), 177–186.
24. [24] Bateman, E.D., Goehring, U.M., Richard, F., Watz, H., Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J. Allergy Clin. Immunol., 2016 Feb 23, S0091–S6749.